Dorthe Lisbeth Jeppesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorthe Lisbeth Jeppesen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Christine Stabell Benn
Bandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau; Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark
3 shared publications - Jesper Kjærgaard
Unit for children and adolescents with infections or organ-disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
2 shared publications - Lone Graff Stensballe
Department of Paediatrics and Adolescent Medicine Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark
2 shared publications - Nina Marie Birk
Department of Pediatrics, Copenhagen University Hospital, Hvidovre, Denmark
2 shared publications - Ole Pryds
Department of Pediatrics, Copenhagen University Hospital, Hvidovre, Denmark
2 shared publications - Peter Aaby
Southern Danish University
2 shared publications
Latest Publications
- Open Access
- 3 August 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-8
The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants
The Bacillus Calmette-Guérin vaccine (BCG) against tuberculosis is administered intradermally, and vaccination is often followed by a scar at the injection site. Among BCG-vaccinated individuals, having a scar has been associated with lower mortality. We aimed to examine the impact of vaccination technique for scarring in a high income setting, by assessing the associations between the post injection reaction, the wheal size, and the probability of developing a scar, and scar size. This study was nested within a clinical multicenter study randomizing 4262 infants to either BCG vaccination (BCG 1331 SSI) or no intervention. In this substudy, including 492 vaccinated infants, the immediate post BCG vaccination reaction was registered as either wheal (a raised, blanched papule at the injection site), bulge (a palpable element at the injection site), or no reaction. The presence or absence of a BCG scar and the size the scar was measured at 13 months of age. Of 492 infants included, 87% had a wheal after vaccination, 11% had a bulge, and 2% had no reaction. The mean wheal size was 3.8 mm (95% confidence interval 3.7–3.9). Overall, 95% (442/466, 26 lost to follow-up) of BCG-vaccinated infants had a scar at 13 months of age. In infants with a wheal, the probability of developing a scar was 96%, declining to 87% in the case of a bulge, and to 56% in the case of no reaction (p for same probability = 0.03). Wheal size was positively correlated with the probability of getting a scar and scar size. Scarring after BCG vaccination has been associated with lower infant mortality. In a high-income setting, we found that correct injection technique is highly important for the development of a BCG scar and that registration of the category of BCG skin reaction (as wheal, bulge, or no reaction) may be used to identify infants at risk of scar failure. Finally, the wheal size was positively associated with both the probability of getting a scar and scar size. The study was registered at www.ClinicalTrials.gov with trial registration number NCT01694108 .
- 3 August 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-8
Open AccessThe association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants
The Bacillus Calmette-Guérin vaccine (BCG) against tuberculosis is administered intradermally, and vaccination is often followed by a scar at the injection site. Among BCG-vaccinated individuals, having a scar has been associated with lower mortality. We aimed to examine the impact of vaccination technique for scarring in a high income setting, by assessing the associations between the post injection reaction, the wheal size, and the probability of developing a scar, and scar size. This study was nested within a clinical multicenter study randomizing 4262 infants to either BCG vaccination (BCG 1331 SSI) or no intervention. In this substudy, including 492 vaccinated infants, the immediate post BCG vaccination reaction was registered as either wheal (a raised, blanched papule at the injection site), bulge (a palpable element at the injection site), or no reaction. The presence or absence of a BCG scar and the size the scar was measured at 13 months of age. Of 492 infants included, 87% had a wheal after vaccination, 11% had a bulge, and 2% had no reaction. The mean wheal size was 3.8 mm (95% confidence interval 3.7–3.9). Overall, 95% (442/466, 26 lost to follow-up) of BCG-vaccinated infants had a scar at 13 months of age. In infants with a wheal, the probability of developing a scar was 96%, declining to 87% in the case of a bulge, and to 56% in the case of no reaction (p for same probability = 0.03). Wheal size was positively correlated with the probability of getting a scar and scar size. Scarring after BCG vaccination has been associated with lower infant mortality. In a high-income setting, we found that correct injection technique is highly important for the development of a BCG scar and that registration of the category of BCG skin reaction (as wheal, bulge, or no reaction) may be used to identify infants at risk of scar failure. Finally, the wheal size was positively associated with both the probability of getting a scar and scar size. The study was registered at www.ClinicalTrials.gov with trial registration number NCT01694108 .